As part of the current consolidation of LCDs within National Government Services Medicare contracts, National Government Services Part A - New York will retire the Local Coverage Determinations (LCDs) listed below, effective November 30, 2007. These retired LCDs will be superseded by the consolidated LCDs listed in the last column, effective December 1, 2007.
Part A New York LCDs Being Retired 11/30/2007 |
LCD Number |
National Government Services LCDs Superseding Part A New York LCDs - Effective 12/01/2007 |
Aloxi (Palenosetron Hydrochloride) |
L17580 |
Drugs and Biologicals, Coverage of, for Label and Off-Label Uses - L25820 |
Aranesp (Darbepoetin Alfa) for ESRD Use |
L19140 |
Erythropoietin Stimulating Agents(ESA) - L25211 |
Beta Glucocerebrosidase and Analogues |
L2206 |
Drugs and Biologicals, Coverage of, for Label and Off-Label Uses - L25820 |
CT Colonography (Virtual Colonoscopy) |
L17586 |
Computed Tomographic (CT) Colonography - L25233 |
Erythropoietin (Epoetin Alpha, EPO) for ESRD Use |
L13700 |
Erythropoietin Stimulating Agents(ESA) - L25211 |
Fluorescein Angiography - |
L2170 |
Ophthalmic Angiography (Fluorescein and Indocyanine Green) - L25347 |
Human Skin Equivalent |
L22620 |
Biologic Products for Wound Treatment and Surgical Interventions - L26003 |
Hyaluronase Polymers |
L671 |
Drugs and Biologicals, Coverage of, for Label and Off-Label Uses - L25820 |
Magnetic Resonance Angiography |
L513 |
Magnetic Resonance Angiography (MRA) - L25367 |
Sclerotherapy for Varicose Veins of the Lower Extremities with or without Doppler/Duplex Guidance |
L659 |
Varicose Veins of the Lower Extremity, Treatment of - L25519 |
Zoledronic Acid |
L690 |
Drugs and Biologicals, Coverage of, for Label and Off-Label Uses - L25820 |